Yesterday French pharmaceutical company Transgene announced that it incorporated the blockchain supply chain traceability platform Hypertrust X-Chain into its clinical trials project myvac.
Through myvac, Transgene is undertaking clinical trials to create individualized immunotherapy products. The program analyses cells from individuals and uses unique neoantigens (patient-specific mutations) to create a tailored vaccine that helps the immune system recognize and attack cancer cells.
The process is delicate and requires immutable and tamperproof data from all areas of the supply chain. This is especially relevant as the supply chain involves numerous organizations.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
